{"entity":{"type":"insider","cik":"0001817160","url":"/insider/0001817160","json_url":"/insider/0001817160.json","name":"Hansen Gwenn","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":41,"n_filings":37,"first":"2021-02-22","last":"2026-08-05","span_basis":"filed_date"},"name_variants":[{"name":"Hansen Gwenn","source":"filing","n_filings":37,"first_seen":"2021-02-22","last_seen":"2026-08-05"}],"transactions":[{"id":5779358,"accession":"0001817160-26-000017","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001817160-26-000017","line_url":"/filing/0001817160-26-000017#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4356.0,"shares_display":"4,356","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":108900.0,"total_display":"108,900.00","total_whole":"108,900","shares_owned_after":117227.0,"shares_owned_after_display":"117,227","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-05","filed_date":"2026-08-05","scope":"insider"},{"id":5841016,"accession":"0001817160-26-000015","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001817160-26-000015","line_url":"/filing/0001817160-26-000015","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4111.0,"shares_display":"4,111","price_per_share":24.35941534906349,"price_display":"24.36","price_state":"stated","total_value":100141.5565,"total_display":"100,141.56","total_whole":"100,142","shares_owned_after":117227.0,"shares_owned_after_display":"117,227","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-04","filed_date":"2026-08-05","scope":"insider","n_lines":2},{"id":6225577,"accession":"0001817160-26-000012","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001817160-26-000012","line_url":"/filing/0001817160-26-000012#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3847.0,"shares_display":"3,847","price_per_share":23.3828,"price_display":"23.38","price_state":"stated","total_value":89953.6316,"total_display":"89,953.63","total_whole":"89,954","shares_owned_after":121338.0,"shares_owned_after_display":"121,338","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-30","filed_date":"2026-07-30","scope":"insider"},{"id":6180640,"accession":"0001817160-26-000010","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001817160-26-000010","line_url":"/filing/0001817160-26-000010#line-1","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5394.0,"shares_display":"5,394","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":107880.0,"total_display":"107,880.00","total_whole":"107,880","shares_owned_after":115005.0,"shares_owned_after_display":"115,005","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-25","filed_date":"2026-06-25","scope":"insider"},{"id":6005357,"accession":"0001817160-26-000008","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001817160-26-000008","line_url":"/filing/0001817160-26-000008#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3214.0,"shares_display":"3,214","price_per_share":16.6453,"price_display":"16.65","price_state":"stated","total_value":53497.9942,"total_display":"53,497.99","total_whole":"53,498","shares_owned_after":120399.0,"shares_owned_after_display":"120,399","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-30","filed_date":"2026-04-30","scope":"insider"},{"id":5900031,"accession":"0001817160-26-000002","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001817160-26-000002","line_url":"/filing/0001817160-26-000002","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4895.0,"shares_display":"4,895","price_per_share":16.598398120531154,"price_display":"16.60","price_state":"stated","total_value":81249.1588,"total_display":"81,249.16","total_whole":"81,249","shares_owned_after":83770.0,"shares_owned_after_display":"83,770","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-30","filed_date":"2026-01-30","scope":"insider","n_lines":2},{"id":4284656,"accession":"0001817160-25-000005","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001817160-25-000005","line_url":"/filing/0001817160-25-000005#line-5","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4087.0,"shares_display":"4,087","price_per_share":12.7967,"price_display":"12.80","price_state":"stated","total_value":52300.1129,"total_display":"52,300.11","total_whole":"52,300","shares_owned_after":76751.0,"shares_owned_after_display":"76,751","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-30","filed_date":"2025-10-30","scope":"insider"},{"id":4865353,"accession":"0001549595-25-000099","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001549595-25-000099","line_url":"/filing/0001549595-25-000099#line-5","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4308.0,"shares_display":"4,308","price_per_share":12.011,"price_display":"12.01","price_state":"stated","total_value":51743.388,"total_display":"51,743.39","total_whole":"51,743","shares_owned_after":69023.0,"shares_owned_after_display":"69,023","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-30","filed_date":"2025-07-30","scope":"insider"},{"id":5214870,"accession":"0001549595-25-000061","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001549595-25-000061","line_url":"/filing/0001549595-25-000061#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3377.0,"shares_display":"3,377","price_per_share":11.5017,"price_display":"11.50","price_state":"stated","total_value":38841.2409,"total_display":"38,841.24","total_whole":"38,841","shares_owned_after":61516.0,"shares_owned_after_display":"61,516","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-30","filed_date":"2025-04-30","scope":"insider"},{"id":5214860,"accession":"0001549595-25-000022","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001549595-25-000022","line_url":"/filing/0001549595-25-000022","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3690.0,"shares_display":"3,690","price_per_share":19.853618536585365,"price_display":"19.85","price_state":"stated","total_value":73259.8524,"total_display":"73,259.85","total_whole":"73,260","shares_owned_after":56270.0,"shares_owned_after_display":"56,270","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-30","filed_date":"2025-01-30","scope":"insider","n_lines":2},{"id":2788849,"accession":"0001549595-24-000147","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001549595-24-000147","line_url":"/filing/0001549595-24-000147#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3437.0,"shares_display":"3,437","price_per_share":24.305,"price_display":"24.30","price_state":"stated","total_value":83536.285,"total_display":"83,536.28","total_whole":"83,536","shares_owned_after":50670.0,"shares_owned_after_display":"50,670","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-30","filed_date":"2024-10-30","scope":"insider"},{"id":2160371,"accession":"0001549595-24-000106","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001549595-24-000106","line_url":"/filing/0001549595-24-000106#line-4","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3408.0,"shares_display":"3,408","price_per_share":20.6677,"price_display":"20.67","price_state":"stated","total_value":70435.5216,"total_display":"70,435.52","total_whole":"70,436","shares_owned_after":45150.0,"shares_owned_after_display":"45,150","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-30","filed_date":"2024-07-30","scope":"insider"},{"id":3049927,"accession":"0001549595-24-000054","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001549595-24-000054","line_url":"/filing/0001549595-24-000054#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2007.0,"shares_display":"2,007","price_per_share":12.0422,"price_display":"12.04","price_state":"stated","total_value":24168.6954,"total_display":"24,168.70","total_whole":"24,169","shares_owned_after":39601.0,"shares_owned_after_display":"39,601","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-30","filed_date":"2024-04-30","scope":"insider"},{"id":2287812,"accession":"0001549595-24-000008","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001549595-24-000008","line_url":"/filing/0001549595-24-000008#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2334.0,"shares_display":"2,334","price_per_share":7.9902,"price_display":"7.99","price_state":"stated","total_value":18649.1268,"total_display":"18,649.13","total_whole":"18,649","shares_owned_after":36402.0,"shares_owned_after_display":"36,402","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-30","filed_date":"2024-01-30","scope":"insider"},{"id":8735038,"accession":"0001549595-23-000058","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001549595-23-000058","line_url":"/filing/0001549595-23-000058#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1633.0,"shares_display":"1,633","price_per_share":5.1974,"price_display":"5.20","price_state":"stated","total_value":8487.3542,"total_display":"8,487.35","total_whole":"8,487","shares_owned_after":33529.0,"shares_owned_after_display":"33,529","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-31","filed_date":"2023-11-01","scope":"insider"},{"id":8608453,"accession":"0001209191-23-043975","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-23-043975","line_url":"/filing/0001209191-23-043975#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1884.0,"shares_display":"1,884","price_per_share":9.6547,"price_display":"9.65","price_state":"stated","total_value":18189.4548,"total_display":"18,189.45","total_whole":"18,189","shares_owned_after":29955.0,"shares_owned_after_display":"29,955","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-31","filed_date":"2023-08-01","scope":"insider"},{"id":7968959,"accession":"0001209191-23-026515","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-026515","line_url":"/filing/0001209191-23-026515#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1136.0,"shares_display":"1,136","price_per_share":9.8763,"price_display":"9.88","price_state":"stated","total_value":11219.4768,"total_display":"11,219.48","total_whole":"11,219","shares_owned_after":26632.0,"shares_owned_after_display":"26,632","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-01","filed_date":"2023-05-02","scope":"insider"},{"id":8627233,"accession":"0001209191-23-005904","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-23-005904","line_url":"/filing/0001209191-23-005904#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1412.0,"shares_display":"1,412","price_per_share":11.7796,"price_display":"11.78","price_state":"stated","total_value":16632.7952,"total_display":"16,632.80","total_whole":"16,633","shares_owned_after":23009.0,"shares_owned_after_display":"23,009","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-30","filed_date":"2023-02-01","scope":"insider"},{"id":6518156,"accession":"0001209191-22-055138","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-055138","line_url":"/filing/0001209191-22-055138#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1165.0,"shares_display":"1,165","price_per_share":12.8805,"price_display":"12.88","price_state":"stated","total_value":15005.7825,"total_display":"15,005.78","total_whole":"15,006","shares_owned_after":21214.0,"shares_owned_after_display":"21,214","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-10-31","filed_date":"2022-11-01","scope":"insider"},{"id":6149174,"accession":"0001209191-22-043961","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-043961","line_url":"/filing/0001209191-22-043961#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1186.0,"shares_display":"1,186","price_per_share":15.67,"price_display":"15.67","price_state":"stated","total_value":18584.62,"total_display":"18,584.62","total_whole":"18,585","shares_owned_after":19172.0,"shares_owned_after_display":"19,172","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-08-01","filed_date":"2022-08-02","scope":"insider"},{"id":6098226,"accession":"0001209191-22-026892","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-026892","line_url":"/filing/0001209191-22-026892#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1098.0,"shares_display":"1,098","price_per_share":11.75,"price_display":"11.75","price_state":"stated","total_value":12901.5,"total_display":"12,901.50","total_whole":"12,902","shares_owned_after":17151.0,"shares_owned_after_display":"17,151","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-05-02","filed_date":"2022-05-03","scope":"insider"},{"id":6480323,"accession":"0001209191-22-000730","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-000730","line_url":"/filing/0001209191-22-000730#line-3","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1828.0,"shares_display":"1,828","price_per_share":28.96,"price_display":"28.96","price_state":"stated","total_value":52938.88,"total_display":"52,938.88","total_whole":"52,939","shares_owned_after":14197.0,"shares_owned_after_display":"14,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-01-03","filed_date":"2022-01-04","scope":"insider"},{"id":5406950,"accession":"0001209191-21-067685","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-067685","line_url":"/filing/0001209191-21-067685#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":29.13,"price_display":"29.13","price_state":"stated","total_value":11652.0,"total_display":"11,652.00","total_whole":"11,652","shares_owned_after":14197.0,"shares_owned_after_display":"14,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-01","filed_date":"2021-12-02","scope":"insider"},{"id":5531534,"accession":"0001209191-21-062466","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-062466","line_url":"/filing/0001209191-21-062466#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":33.24,"price_display":"33.24","price_state":"stated","total_value":13296.0,"total_display":"13,296.00","total_whole":"13,296","shares_owned_after":14197.0,"shares_owned_after_display":"14,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-11-01","filed_date":"2021-11-02","scope":"insider"},{"id":4540342,"accession":"0001209191-21-061973","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-061973","line_url":"/filing/0001209191-21-061973#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":14000.0,"total_display":"14,000.00","total_whole":"14,000","shares_owned_after":14197.0,"shares_owned_after_display":"14,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-27","filed_date":"2021-10-28","scope":"insider"},{"id":4956364,"accession":"0001209191-21-059064","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-059064","line_url":"/filing/0001209191-21-059064#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":29.92,"price_display":"29.92","price_state":"stated","total_value":11968.0,"total_display":"11,968.00","total_whole":"11,968","shares_owned_after":14197.0,"shares_owned_after_display":"14,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-10-01","filed_date":"2021-10-04","scope":"insider"},{"id":4732058,"accession":"0001209191-21-055171","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-055171","line_url":"/filing/0001209191-21-055171#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1600.0,"shares_display":"1,600","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":56000.0,"total_display":"56,000.00","total_whole":"56,000","shares_owned_after":14197.0,"shares_owned_after_display":"14,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-07","filed_date":"2021-09-08","scope":"insider"},{"id":5001439,"accession":"0001209191-21-054434","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-054434","line_url":"/filing/0001209191-21-054434#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":32.34,"price_display":"32.34","price_state":"stated","total_value":12936.0,"total_display":"12,936.00","total_whole":"12,936","shares_owned_after":14197.0,"shares_owned_after_display":"14,197","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-09-01","filed_date":"2021-09-02","scope":"insider"},{"id":4623383,"accession":"0001209191-21-049420","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-049420","line_url":"/filing/0001209191-21-049420#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":31.21,"price_display":"31.21","price_state":"stated","total_value":12484.0,"total_display":"12,484.00","total_whole":"12,484","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-08-02","filed_date":"2021-08-03","scope":"insider"},{"id":4484774,"accession":"0001209191-21-044868","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-044868","line_url":"/filing/0001209191-21-044868#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":26.76,"price_display":"26.76","price_state":"stated","total_value":10704.0,"total_display":"10,704.00","total_whole":"10,704","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-01","filed_date":"2021-07-02","scope":"insider"},{"id":4180759,"accession":"0001209191-21-037263","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-037263","line_url":"/filing/0001209191-21-037263#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":27.74,"price_display":"27.74","price_state":"stated","total_value":11096.0,"total_display":"11,096.00","total_whole":"11,096","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-01","filed_date":"2021-06-02","scope":"insider"},{"id":5250331,"accession":"0001209191-21-029883","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-029883","line_url":"/filing/0001209191-21-029883#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":800.0,"shares_display":"800","price_per_share":34.995,"price_display":"35.00","price_state":"stated","total_value":27996.0,"total_display":"27,996.00","total_whole":"27,996","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-04","scope":"insider"},{"id":4783803,"accession":"0001209191-21-025649","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-025649","line_url":"/filing/0001209191-21-025649#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":14000.0,"total_display":"14,000.00","total_whole":"14,000","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-05","filed_date":"2021-04-06","scope":"insider"},{"id":5147335,"accession":"0001209191-21-024711","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-024711","line_url":"/filing/0001209191-21-024711#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":400.0,"shares_display":"400","price_per_share":31.55,"price_display":"31.55","price_state":"stated","total_value":12620.0,"total_display":"12,620.00","total_whole":"12,620","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-01","filed_date":"2021-04-02","scope":"insider"},{"id":5322882,"accession":"0001209191-21-021092","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-021092","line_url":"/filing/0001209191-21-021092#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":800.0,"shares_display":"800","price_per_share":45.0,"price_display":"45.00","price_state":"stated","total_value":36000.0,"total_display":"36,000.00","total_whole":"36,000","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-16","filed_date":"2021-03-16","scope":"insider"},{"id":4223909,"accession":"0001209191-21-016301","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-016301","line_url":"/filing/0001209191-21-016301#line-2","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":800.0,"shares_display":"800","price_per_share":35.95,"price_display":"35.95","price_state":"stated","total_value":28760.0,"total_display":"28,760.00","total_whole":"28,760","shares_owned_after":13804.0,"shares_owned_after_display":"13,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-02","scope":"insider"},{"id":5488976,"accession":"0001209191-21-012662","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-012662","line_url":"/filing/0001209191-21-012662","is_derivative":false,"issuer_cik":"0001549595","issuer_name":"Nurix Therapeutics, Inc.","issuer_ticker":"NRIX","issuer_name_source":null,"issuer_url":"/issuer/0001549595","owner_cik":"0001817160","owner_name":"Hansen Gwenn","owner_display_name":"Hansen Gwenn","owner_url":"/insider/0001817160","role":"Officer (Chief Scientific Officer)","role_mark":"O","role_mark_label":"Officer (Chief Scientific Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Scientific Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":800.0,"shares_display":"800","price_per_share":36.272525,"price_display":"36.27","price_state":"stated","total_value":29018.02,"total_display":"29,018.02","total_whole":"29,018","shares_owned_after":12200.0,"shares_owned_after_display":"12,200","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-18","filed_date":"2021-02-22","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":41,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":41,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":41},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001549595","name":"Nurix Therapeutics, Inc.","url":"/issuer/0001549595","role":"Officer (Chief Scientific Officer)","n_filings":37,"first_seen":"2021-02-22","last_seen":"2026-08-05"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001817160","retrieved_at":"2026-08-23T22:01:21+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}